Enes Erul, Oncology Fellow at Ankara University, shared OncoDaily’s post on LinkedIn:
“Today I joined American Society of Clinical Oncology (ASCO) Molecular Tumor Boards ECHO Series, starting with Session 1 on the role of MTBs in precision oncology.
Topics include MTB workflow, clinical actionability scales, and real-world challenges (testing access, reimbursement, off-label justification, and clinical trial pathways), along with practical interpretation questions such as low-VAF liquid biopsy and whether/when to repeat molecular testing at progression.
I want to emphasize what an incredible opportunity American Society of Clinical Oncology (ASCO) continues to create for clinicians like us through this ECHO program bringing world-class expertise, practical frameworks, and real-world discussion into our daily practice. My sincere thanks to the faculty and organizers for their time, guidance, and commitment to advancing precision oncology across the region.”